Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 3;13(4):609.
doi: 10.3390/brainsci13040609.

Clinical Evaluation of Sleep Disorders in Parkinson's Disease

Fulvio Lauretani  1   2 , Crescenzo Testa  1 , Marco Salvi  1 , Irene Zucchini  1 , Francesco Giallauria  3 , Marcello Maggio  1   2
Affiliations
Review

Clinical Evaluation of Sleep Disorders in Parkinson's Disease

Fulvio Lauretani et al. Brain Sci. .

Abstract

The paradigm of the framing of Parkinson's disease (PD) has undergone significant revision in recent years, making this neurodegenerative disease a multi-behavioral disorder rather than a purely motor disease. PD affects not only the "classic" substantia nigra at the subthalamic nuclei level but also the nerve nuclei, which are responsible for sleep regulation. Sleep disturbances are the clinical manifestations of Parkinson's disease that most negatively affect the quality of life of patients and their caregivers. First-choice treatments for Parkinson's disease determine amazing effects on improving motor functions. However, it is still little known whether they can affect the quantity and quality of sleep in these patients. In this perspective article, we will analyze the treatments available for this specific clinical setting, hypothesizing a therapeutic approach in relation to neurodegenerative disease state.

Keywords: Braak’s stages; Parkinson’s disease; drugs; sleep disorders; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA diagram of selection process.
Figure 2
Figure 2
Correlation between the Braak scale in Parkinson’s disease and symptom presentation. In sleep disorders, the indications for pharmacological therapy depend on the multidimensional evaluation of the patient.
See this image and copyright information in PMC

References

    1. Zhang S., Smailagic N., Hyde C., Noel-Storr A.H., Takwoingi Y., McShane R., Feng J. (11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) Cochrane Database Syst. Rev. 2014;7:CD010386. doi: 10.1002/14651858.CD010386.pub2. - DOI - PMC - PubMed
    1. Hou Y., Dan X., Babbar M., Wei Y., Hasselbalch S.G., Croteau D.L., Bohr V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019;15:565–581. doi: 10.1038/s41582-019-0244-7. - DOI - PubMed
    1. Testa C., DILorenzo A., Parlato A., D’Ambrosio G., Merolla A., Pacileo M., Iannuzzo G., Gentile M., Nugara C., Sarullo F.M., et al. Exercise for slowing the progression of atherosclerotic process: Effects on inflammatory markers. Panminerva Med. 2021;63:122–132. doi: 10.23736/S0031-0808.21.04266-X. - DOI - PubMed
    1. Madetko N., Migda B., Alster P., Turski P., Koziorowski D., Friedman A. Platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns. Neurol. Neurochir. Pol. 2022;56:148–155. doi: 10.5603/PJNNS.a2022.0014. - DOI - PubMed
    1. Dumbhare O., Gaurkar S.S. A Review of Genetic and Gene Therapy for Parkinson’s Disease. Cureus. 2023;15:e34657. doi: 10.7759/cureus.34657. - DOI - PMC - PubMed

LinkOut - more resources